Baxfendy (baxdrostat), a small molecule drug in-licensed and developed by AstraZeneca Plc, has been approved by the US Food and Drug Administration to treat adults with hypertension – a disease estimated to affect 1.4 billion people worldwide and a leading risk factor for cardiovascular disease and premature death. Announced on 18 May, the approval is for the use of Baxfendy in combination with other antihypertensive medicines to lower blood pressure in adults who are not adequately controlled.
